Exact Sciences
5505 Endeavor Lane
Madison
WI
53719
United States
Tel: 608.284.5700
Website: http://www.exactsciences.com/
Email: jobs@exactsciences.com
519 articles about Exact Sciences
-
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
4/15/2024
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced the appointment of Aaron Bloomer as chief financial officer, effective May 15, 2024.
-
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
4/4/2024
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
-
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
3/28/2024
Exact Sciences Corp. in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma and its precursors, including Barrett’s esophagus.1,2 Findings from the test’s algorithm training and testing were recently published in the Clinical Gastroenterology and Hepatology journal.
-
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
3/27/2024
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced it has received the 2024 Gallup Exceptional Workplace Award.
-
Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States
2/28/2024
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced the launch of the Riskguard™ hereditary cancer test in the United States.
-
Exact Sciences to Participate in March 2024 Investor Conference
2/26/2024
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.
-
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
1/7/2024
Exact Sciences Corp. announced that the company expects to report revenue between $645.5 million and $647.5 million for the fourth quarter ended December 31, 2023.
-
Exact Sciences to participate in J.P. Morgan Healthcare Conference - January 2, 2024
1/2/2024
Exact Sciences Corp. today announced that company management will participate in the following conference and invited investors to participate by webcast.
-
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
12/7/2023
Exact Sciences announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program.
-
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
11/30/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium.
-
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
11/17/2023
Exact Sciences Corp. today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware.
-
Exact Sciences to participate in November 2023 investor conferences
11/1/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conferences and invited investors to participate by webcast.
-
Exact Sciences Announces Third-Quarter 2023 Results
11/1/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company generated revenue of $628.3 million for the third quarter ended September 30, 2023, compared to $523.1 million for the same period of 2022.
-
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection
10/22/2023
Exact Sciences Corp. announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer at 91% specificity, during the American College of Gastroenterology Annual Meeting 2023.
-
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
10/9/2023
Exact Sciences Corp. announced the company will present late-breaking data on next-generation Cologuard® from the BLUE-C pivotal trial during the American College of Gastroenterology Annual Meeting, taking place October 20-25, 2023, in Vancouver, Canada.
-
Exact Sciences schedules third quarter 2023 earnings call
10/9/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023.
-
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
9/12/2023
Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences.
-
Exact Sciences to participate in September 2023 investor conference
9/1/2023
Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.
-
Exact Sciences Announces Second-Quarter 2023 Results
8/1/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022.
-
Exact Sciences schedules second quarter 2023 earnings call
7/10/2023
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its second quarter 2023 financial results after the close of the U.S. financial markets on August 1, 2023.